Coagulation defects in cyclosporine A treated allogeneic bone marrow transplant patients.
CSA toxicity includes renal impairment, microangiopathic hemolytic anemia (MAHA), thrombocytopenia (T), and consumptive coagulopathy (CC). We report five BMT patients who developed CSA-associated hematological toxicity. All were conditioned with Ara-C, Cyclophosphamide, Methylprednisolone, TBI, and in two cases busulfan. IV CSA was started the day after marrow infusion and, when practicable, changed to the enteral route. Five patients developed MAHA and T resulting in significantly increased transfusion requirements. All patients had renal impairment and red cell fragmentation. In all patients fragmentation was noted before renal impairment. All developed disproportionate increases in BUN relative to serum creatinine consistent with decreased renal perfusion. Hypertension followed renal impairment in four cases and occurred at the same time as the renal impairment in one case. Two developed CC, prolongation in APTT, and marked decreases in plasma fibrinogen. All patients improved on reduction of the CSA dose. BMT recipients receiving CSA at variable doses may develop evidence of a TTP-like syndrome and/or CC.
D000293:Adolescent; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents; D007223:Infant; D007945:Leukemia, Lymphoid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D011183:Postoperative Complications; D014184:Transplantation, Homologous
D003524:Cyclosporins; D007166:Immunosuppressive Agents